Dataset Information

Modified fish diet in six dolphins

ABSTRACT: Feeding a modified fish diet has been suggested to improve insulin sensitivity in bottlenose dolphins; however insulin sensitivity was not directly measured. Since demonstrating an improvement in insulin sensitivity is technically difficult in dolphins, we postulated that directional changes in the hormone axis: fibroblast growth factor 21 (FGF21)/Adiponectin/Ceramide (Cer), could provide further support to this hypothesis. Proteomic analysis of the serum proteins revealed few changes in serum proteins over the study period. In conclusion, changing the types of fish fed to dolphins resulted in increases in the insulin sensitizing hormone adiponectin and serum sphingosines consistent with an insulin sensitizing phenotype.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Tursiops Truncatus (atlantic Bottle-nosed Dolphin) (delphinus Truncatus)

TISSUE(S): Blood Serum

SUBMITTER: Philip Sobolesky

LAB HEAD: Michael G. Janech

PROVIDER: PXD003425 | Pride | 2016-04-20

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	2015_09_15 USN MMP Animal E - 0 15-3 F001914.pride.mztab.gz	Mztab
	2015_09_15 USN MMP Animal E - 0 15-3.pride.mgf.gz	Mgf
	2015_09_15 USN MMP Animal E - 0 30-3 F001915.pride.mztab.gz	Mztab
	2015_09_15 USN MMP Animal E - 0 30-3.pride.mgf.gz	Mgf
	2015_09_15 USN MMP Animal E - 12 15-3 F001920.pride.mztab.gz	Mztab

Items per page:

1 - 5 of 490

Similar Datasets

Project description:Background/aims: Serum concentrations of the hepatokine fibroblast growth factor (FGF) 21 are elevated in obesity, type‐2 diabetes, and the metabolic syndrome. We asked whether FGF21 levels differ between subjects with metabolically healthy vs. unhealthy obesity (MHO vs. MUHO) opening the possibility that FGF21 is a cross‐talker between liver and adipose tissue in MUHO. Furthermore, we studied the effects of chronic FGF21 treatment on adipocyte differentiation, lipid storage, and adipokine secretion. Methods/study design: In 20 morbidly obese donors of abdominal subcutaneous fat biopsies discordant for their whole‐body insulin sensitivity (hereby classified as MHO or MUHO subjects), serum FGF21 was quantified. The impact of chronic FGF21 treatment on differentiation, lipid accumulation, and adipokine release was assessed in isolated preadipocytes differentiated in vitro. Results: Serum FGF21 concentrations were more than two‐fold higher in MUHO as compared to 37 MHO subjects (457 ±378 vs. 211 ±123 pg/mL; p<0.05). FGF21 treatment of human preadipocytes for the entire differentiation period was modestly lipogenic (+15%; p<0.05), reduced the expression of key adipogenic transcription factors (PPARG and CEBPA, ‐15% and ‐40%, respectively; p<0.01 both), reduced adiponectin expression (‐20%; p<0.05), markedly reduced adiponectin release (‐60%; p<0.01), and substantially increased leptin (+60%; p<0.01) and interleukin‐6 (+50%; p<0.001) release. Interpretation/conclusions: The hepatokine FGF21 exerts weak lipogenic and anti‐adipogenic actions and marked adiponectin‐suppressive and leptin and interleukin‐6 release‐promoting effects in human differentiating preadipocytes. Together with the higher serum concentrations in MUHO subjects, our findings reveal FGF21 as a circulating factor promoting the development of metabolically unhealthy adipocytes. We analysed in vitro differentiated preadipocytes from 20 human donors treated with FGF21 or control cultures.

Dataset Information

Modified fish diet in six dolphins

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets